Skip to content

EBITDA margin at other companies

LivaNova logo
LivaNovaLIVN
16.8%+1.3pp
ICU Medical logo
ICU MedicalICUI
11.4%-0.2pp
Edwards Lifesciences logo
Edwards LifesciencesEW
23.9%-4.6pp
United Therapeutics logo
United TherapeuticsUTHR
48.1%-1.4pp
OSI Systems logo
OSI SystemsOSIS
14.3%-0.6pp

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.55B+50.6%
Enterprise value$2.5B+66.0%
P/E14.8×-19.8×
P/S+0.5×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Calculated from TransMedics Group, Inc.’s reported figures.

Based on trailing twelve months.

The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TransMedics Group, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TransMedics Group, Inc.'s EBITDA margin?
TransMedics Group, Inc. (TMDX) reported EBITDA margin of 20% in Q1 2026.
How has TransMedics Group, Inc.'s EBITDA margin changed year-over-year?
TransMedics Group, Inc.'s EBITDA margin increased by 31.9% year-over-year, from 15.2% to 20%.
What is the long-term trend for TransMedics Group, Inc.'s EBITDA margin?
Over 5 years (2020 to 2025), TransMedics Group, Inc.'s EBITDA margin has grown at a -25.4% compound annual growth rate (CAGR), from -96.8% to 22.4%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.